The acquisition signals BioNTech's intent to file a late-stage oncology asset for FDA approval in the near-to-medium term. Monitor for which specific pipeline candidate will use the voucher and for updates on HSR clearance.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $87.21entry
- T+1 · 6d ago +0.50%α −0.81% · $87.65
- T+4 · todayOpen
- T+5 · in 10h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech announced it will acquire an FDA Priority Review Voucher from Scholar Rock for $205 million in cash. The PRV will be used to support a future regulatory filing for a late-stage oncology asset, potentially accelerating approval timelines.
Key Facts
- BioNTech agreed to acquire an FDA Priority Review Voucher from Scholar Rock for $205 million in cash.
- The PRV reduces the FDA review timeline for a single application and could lead to expedited approval.
- BioNTech intends to use the PRV to support a future filing of an asset in its late-stage oncology pipeline.
- The transaction is subject to customary closing conditions, including HSR antitrust clearance.
Financial Impact
$205 million cash consideration, representing approximately 0.9% of BioNTech's $22.0 billion market cap.
Risk Factors
- The transaction is subject to HSR antitrust clearance and other customary closing conditions.
- The specific asset that will use the PRV has not been disclosed, making it difficult to assess the potential value of the accelerated review.
- A PRV only reduces review time; it does not guarantee approval or affect the clinical data required for approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000083 |
| Document: a991261109_prvxbntstatement.htm | 0001776985-26-000083 |
| Document: 0001776985-26-000083-index-headers.html | 0001776985-26-000083 |
| Document: 0001776985-26-000083-index.html | 0001776985-26-000083 |
| Document: 0001776985-26-000083.txt | 0001776985-26-000083 |
| Earnings Context (Synthetic; results releases only) | 0001776985-26-000083 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Viewing Entry $87.21 Now $85.60 −1.85% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers